A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)

• Protocol code: 1504-0001
• EudraCT code: No aplica
• Research group: Pneumology
• Service: Pneumology
• Principal investigator:  Álvarez Fernandez, Antonio
• Pathology: Malalties del sistema respiratori
• Phase: Fase I